BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval

Priority review designation for the Factor Xa inhibitor suggests FDA sees it as a major treatment advance over Pradaxa and Xarelto in reducing the risk of stroke among atrial fibrillation patients.

FDA’s priority review designation for Bristol-Myers Squibb Co./Pfizer Inc.’s Eliquis (apixaban) suggests the agency believes it offers a major treatment advance over two other recently approved anticoagulants – Pradaxa and Xarelto – in reducing the risk of stroke among atrial fibrillation patients.

BMS and Pfizer announced Nov. 29 that FDA has granted a six-month review for the Factor Xa inhibitor, setting a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America